Clover Health/$CLOV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Clover Health
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
- Ticker
- $CLOV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 724
- Headquarters
- Wilmington, United States
- Website
- www.cloverhealth.com
Clover Health Metrics
BasicAdvanced
$2.4B
-
-$0.04
2.48
-
Price and volume
Market cap
$2.4B
Beta
2.48
52-week high
$5.59
52-week low
$1.58
Average daily volume
3.9M
Financial strength
Current ratio
1.501
Quick ratio
1.379
Profitability
EBITDA (TTM)
-17.956
Gross margin (TTM)
18.54%
Net profit margin (TTM)
-0.74%
Operating margin (TTM)
-0.74%
Revenue per employee (TTM)
$3,420,000
Management effectiveness
Return on assets (TTM)
-1.77%
Return on equity (TTM)
-5.10%
Valuation
Price to revenue (TTM)
0.936
Price to book
6.27
Price to tangible book (TTM)
6.32
Price to free cash flow (TTM)
31.219
Free cash flow yield (TTM)
3.20%
Free cash flow per share (TTM)
0.143
Growth
Revenue change (TTM)
53.98%
Earnings per share change (TTM)
-52.27%
3-year revenue growth (CAGR)
0.47%
3-year earnings per share growth (CAGR)
-57.86%
What the Analysts think about Clover Health
Analyst ratings (Buy, Hold, Sell) for Clover Health stock.
Analyst projections of the future price of Clover Health stock.
Bulls say / Bears say
Medicare Advantage membership rose 48% year on year in Q2 and revenue increased 56%; Clover lifted its 2026 revenue outlook to $2.92bn–$3.00bn. A larger base could help spread fixed costs as the company grows. (GlobeNewswire)
Q2 GAAP net income swung to $28m from a $10.6m loss a year earlier, while adjusted EBITDA rose 139% to $41m; management raised its full-year net income outlook to $20m–$35m. This suggests growth is beginning to translate into earnings. (GlobeNewswire)
Clover reports that year-three members generate about $155 more insurance gross profit per member each month than year-one members, and that Clover Assistant-managed members have an about 18% better medical-cost ratio by year three. If these cohort gains persist, member maturation could improve unit economics. (StockTitan)
Medical claims rose 56.1%, nearly matching insurance revenue growth of 57%, while the benefit expense ratio was still 87.6%. A reversal in medical-cost trends could quickly squeeze the margin left from premiums. (The Motley Fool)
The 4.5-star rating that supports Clover’s 2027 payment outlook followed a court-ordered recalculation, and CMS has appealed the decision. An adverse outcome could reduce the payment flexibility Clover expects from that rating. (Healthcare Finance News, StockTitan)
Clover’s 2026 guidance implies a GAAP net margin of only about 0.7%–1.2% on $2.92bn–$3.00bn of revenue. That leaves little room for claims or administrative costs to come in worse than expected. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Clover Health Financial Performance
Revenues and expenses
Clover Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Clover Health News
AllArticlesVideos
Funds containing Clover Health
Fund name | Fund size | $CLOV weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.17% |
iShares Ageing Population£AGES | $953M | 0.17% |
iShares Ageing Population€AGED | $903M | 0.17% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.